OBJECTIVE: To investigate the related factors of adverse reactions of blood transfusion, and clinical precautions so as to reduce the adverse reactions. METHODS: Data of 2108 patients with allogeneic transfusion in our hospital from January 2017 to June 2017 collected and analyzed. RESULTS: These patients received 15 244 time of blood transfusion, and 213 time of adverse reactions occurred in 178 patients in totality, the incidence is 1.4%, and there was no significant difference between the male (1.31%) and female (1.53%). The main type of transfusion reaction were allergy (73.23%), FNHTR (11.74%) and TACO (10.80%). Among all kinds of blood components, the incidence of adverse reactions of apheresis platelet transfusion was the highest (4.31%), significantly higher than that of cryoprecipitate and other blood components. The incidence rate of adverse reactions of blood transfusion in the hematopathy patients was 2.56%, significantly higher than that of immune diseases (1.48%), cancer diseases (1.28%) and other diseases (1.08%), (P＜0.01). The rate of transfusion history of apheresis platelets was 42.67% (the incidence of adverse reactions was 4.31%), significantly higher than other groups (P＜0.01); the rate of transfusion history of cryoprecipitate was 4.11% (the incidence of adverse reaction was 0.45%), significantly lower than other groups (P＜0.05). Among the disease types, the rate of transfusion history in the hematopathy patients was 48.79% (the incidence of adverse reaction was 2.56%), significantly higher than that of other groups (P＜0.01). The incidence of drug allergy in patients with the adverse reactions to blood transfusion was 11.25%, significantly higher than that of patients without adverse reactions (4.71%) (P＜0.01). CONCLUSION The main risk factors of adverse reactions of blood transfusion are as follows: blood varieties, disease type, transfusion history and drug allergy history. For the patients with transfusion, multiple factors should be controlled, so as to reduce the adverse reactions.
Blood Component Transfusion ; Blood Transfusion ; Female ; Humans ; Hypersensitivity ; Male ; Platelet Transfusion ; Transfusion Reaction

To evaluate flow-cytometry and Nageotte method for counting residual WBC in thrombocytaphoresis concentrates, their accuracies were determined by dilution studies separately; the repeatability was determined by measuring the interassay coefficient of variation for 14 replicates of a sample with known leukocyte concentration. 102 samples of leukocyte-depleted thrombocytaphoresis concentrates were detected by the above mentioned two methods, and the results were compared each other. The results showed that no difference was observed between two methods over a range of leukocyte concentrations from 0.8 to 10 WBC/microl (P > 0.05). In conclusion, flow-cytometry and Nageotte methods can be used for quality control of WBC-reduced blood components.
Blood Component Transfusion ; Evaluation Studies as Topic ; Flow Cytometry ; Humans ; Leukocyte Count ; methods ; Leukocyte Reduction Procedures ; methods ; Plateletpheresis

No abstract available.
Blood Component Transfusion*

OBJECTIVE: To investigate the changes of platelet count (PLT), plateletcrit (PCT), mean platelet volume (MPV) and platelet distribution width (PDW) before and after apheresis platelet transfusion, the correlation between the parameters and their clinical significance. METHODS: A total of 38 patients who received apheresis platelet transfusion were selected, their results of blood routine test closest to the time point of apheresis platelet transfusion were consulted from hospital information system and the changes of PLT, PCT, MPV and PDW were compared before and after transfusion. The correlation between above parameters was analyzed. The correlation of body mass index (BMI) with the increased multiple and increased value after platelet infusion was also analyzed. RESULTS: Compared with pre-infusion, PLT and PCT significantly increased (both P <0.001) while MPV and PDW showed no significant difference after apheresis platelet transfusion (P >0.05). The difference of PLT and PCT before and after apheresis platelet transfusion had no correlation with PLT and PCT before transfusion (r =0.002, r =0.001), while the difference of MPV and PDW was negatively correlated with MPV and PDW before transfusion (r =-0.462, r =-0.610). The PLT growth rate was positively correlated with PCT growth rate before and after apheresis platelet transfusion (r =0.819). BMI was positively correlated with the increased multiple of PLT after infusion (r =0.721), but not with the increased value of PLT after infusion (r =0.374). CONCLUSION Apheresis platelet transfusion can cause platelet parameters change and shows different characteristics. Characteristic changes of platelet parameters and their correlation can be used as reference indices to evaluate the efficacy of apheresis platelet transfusion.
Humans ; Mean Platelet Volume ; Platelet Transfusion ; Blood Platelets ; Platelet Count/methods* ; Blood Component Removal

BACKGROUND: Patients with platelet refractoriness as a result of human leukocyte antigen (HLA) alloimmunization can be effectively managed by transfusion of HLA-matched platelets. In this study, we have retrospectively evaluated the effect of HLA-matched platelet transfusion using a hospital based donor pool of 450 HLA typed donors. METHODS: For 17 patients showing platelet refractoriness to random donor platelets [1 hr corrected count increment (CCI) <7, 500/microliter/m2; mean 1, 887/microliter/m2] and HLA alloimmunization, 78 single-donor apheresis platelets from 62 donors were transfused. HLA compatible donors were selected based on HLA match and patients' HLA antibody specificities. RESULTS: An average of 4.6 transfusions per patient were done and effective post-transfusion platelet increments were obtained with a mean 1 hr CCI of 17, 813/microliter/m2. In 76% (59/78) of the total transfusions, an effective platelet increment (1 hr CCI > or =7, 500/microliter/m2) was obtained. HLA crossmatch (NIH method) negative patients showed a significantly higher platelet increment compared with crossmatch positive patients (23, 877 vs 10, 823; P=0.000). Although better transfusion effect was obtained in higher grade HLA match of A-B2U by selection of HLA compatible donors according to patients' HLA antibody specificities, an effective platelet increment was obtained in lower grade matches as well. Platelets transfused < or =24 hours after collection showed a significantly higher platelet increment compared with those stored >24 hours (20, 325 vs 11, 417; P=0.029). CONCLUSIONS: Although many low grade matched donors were selected due to a relatively small size of HLA typed donor pool, effective platelet increments were obtained by selecting platelet donors on the basis of HLA antibody specificity.
Antibody Specificity ; Blood Component Removal ; Blood Platelets* ; Humans ; Leukocytes ; Platelet Transfusion* ; Retrospective Studies ; Tissue Donors

A retrospective study on the use of total blood and blood preparations from 2001 to November 2002 period was reported. 144,394 units of blood were used, among them, total blood accounts for 41.50%, sedimented red blood cells 31.25%, washed red blood cells 0.88%, fresh freezing plasma 4.60%, concentrated blood plaquettes 13.34%, fresh plasma intensified with white blood cells 4.17%, freezing precipitation with high rate of VIU factor 4.17%. A higher amount of total blood was used in comparing of that of the past year. High efficacy of the use of blood was toted
Blood ; Blood Component Transfusion ; hospitals

BACKGROUND: It is necessary to protect patient from white blood cells (WBC) caused side effects of platelet transfusion by reducing the WBC contamination in single donor platelets (SDPs). Objective of the new software is to improve WBC depletion performance and collection efficiency. Revised software version, LDP Rev. C2 was installed in our MCSR+ (Hemonetics, USA). We compared the newly introduced software version with the previous software LDP Rev. C. METHOD: SDPs were collected from registered and random repeat donors who visited our blood center. After 49 single needle collections by MCSR+ (software LDP Rev. C) were performed, revised software (LDP Rev. C2) was installed and 48 single needle collections were carried out. The platelet count of donors were measured electronically. The target platelet yields were 3.0x10(11). All units of SDPs were tested for platelet yields and residual WBC. And other parameters were also evaluated. RESULTS: The MCSR+ LDP collected platelets with mean platelet yields of 3.3x10(11)(Rev. C) and 3.4x10(11)(Rev. C2). The total processing blood volume and collection time were significantly reduced in Rev. C2. The collection efficiency was also significantly improved in Rev. C2 (64% vs 57%). Residual WBC in all product collected from software Rev. C2 were below 1 106 and 71% of the products revealed residual WBC below 1 105, respectively. Citrate toxicity was not observed during the apheresis by Rev. C2. CONCLUSION: Revised software LDP Rev. C2 in MCSR+ showed improved collection efficiency and leukocyte depletion performance compared to the Rev. C. And optional control of citrate re-infusion rate seemed to reduce donor citrate reactions during the apheresis.
Blood Component Removal ; Blood Platelets ; Blood Volume ; Citric Acid ; Humans ; Leukocytes ; Needles ; Platelet Count ; Platelet Transfusion ; Tissue Donors

BACKGROUND: Leukocytes have been shown to be an undesirable contaminants in platelet transfusions because these contaminants may develop various adverse consequences. Current platelet products by plateletpheresis are heavily contaminated with leukocytes. Recently, new platelet apheresis system (COBE Spectra LRSTM) was designed to make it possible to collect platelets with very low leukocytes contamination. We evaluated the COBE Spectra LRSTM by comparing it with COBE Spectra. METHODS: Plateletpheresis procedures were performed on 75 normal donors; 45 procedures for COBE Spectra LRSTM and 30 procedures for COBE Spectra. We evaluated platelet yields, processing times, efficiency, and leukocytes content on two apheresis machines. RESULTS: Comparative results of COBE Spectra LRSTM with COBE Spectra were as follows: the mean processing time per unit was 97 min and 91 min, the efficiency per unit was 38.4 +/- 11.5% and 46.9 +/- 12.1%, the mean leukocytes contamination per unit was 6.1x104 and 2.1x106 respectively (p<0.01). The platelet yields per unit were 2.79 +/- 1.04x1011 with COBE Spectra LRSTM and 3.13 +/- 0.91x1011 with COBE Spectra (p>0.05). CONCLUSIONS: Platelet collections with COBE Spectra LRSTM demonstrated comparable platelet yields and strikingly low WBC contamination. This study indicate that the COBE Spectra LRSTM is an efficient and reliable system for the collection of platelets with very low residual WBC levels. It seems that leukocyte reduction filter for platelet products by COBE Spectra LRSTM is not necessary for further removal of leukocytes to prevent alloimmunization, non-hemolytic transfusion reactions, certain viral and bacterial infections.
Bacterial Infections ; Blood Component Removal ; Blood Group Incompatibility ; Blood Platelets ; Humans ; Leukocytes ; Platelet Transfusion ; Plateletpheresis ; Tissue Donors

Allergic transfusion reaction (ATR) caused by plasma transfusion is one of the main adverse transfusion reactions, and severe allergic reactions may even endanger the patient's life. Currently, ATR is mainly prevented and controlled by drug prevention and symptomatic treatment, and there still lack of preventive measures such as in vitro experiments. It has been shown that mast cells and basophils are the main effector cells of allergic reactions, and histamine is one of the main mediators of IgE-mediated allergic reactions. Some experiments can be used to identify patients with allergies or plasma components containing allergens, such as detection of serum-specific IgE, IgA, anti-IgA antibody, tryptase and histamine, mast cell degranulation test, basophil activation test, and so on. The basophil activation test can also be used for functional matching of plasma in vitro. Research of in vitro experiment of ATR is good for directing the precise infusion of plasma, reducing waste of resources, and avoiding the risk of blood transfusion. As a pre-transfusion laboratory test for clinical use, in vitro experiment of functional matching provides a new way to prevent ATR.
Blood Component Transfusion ; Blood Transfusion ; Humans ; Hypersensitivity ; Plasma ; Transfusion Reaction

BACKGROUND: The yields of plateletpheresis products are important to meet standard platelet transfusion doses. The use of single donor platelets (SDPs) has been increased substantially worldwide. Korean Red Cross decided to supply and started collection of SDPs since January, 2000. This study evaluates platelet yields of plateletpheresis and plasmapheresis of Korean Red Cross Nambu blood center. METHODS: The records for SDPs collected by Amicus(TM) (Baxter, Deerfield, IL, USA), MCS+ (Haemonetics, Braintree, MA, USA) and Trima (Gambro BCT, Lakewood, USA) between Jan. 2005 and Nov. 2005 were evaluated. The records for plasma collected by Autopheresis-C(TM) (Baxter,Deerfield, IL, USA), MCS(TM), PCS 2 (Haemonetics, Braintree, MA, USA) between Jan. 2005 and Nov. 2005 were also evaluated. RESULTS: Platelet yields of SDP less than 3 x 10(11) accounted for 6.45% of all collections. The rate of SDPs which platelet yields less than 3 x 10(11) collected by AMICUS is 4.84%, MCS+ is 7.72%, TRIMA is 7.01%. The rate of plasmapheresis products under the criteria is 0.7%. Plasma collected with Autopheresis-C(TM) made a concern about break down of filtration pore and occuring of hemolysis during apheresis procedures. CONCLUSION: Platelet yields less than 3 x 10(11) accounted for 6.45% of all collections. The rate of plasmapheresis products under the criteria is 0.7%. This study demonstrated that qualfied management and thorough understanding of the plataletpheresis technology are necessary to increase productivity of SDPs with platelet yields 3x1011 or over.
Blood Component Removal* ; Blood Platelets ; Efficiency ; Filtration ; Hemolysis ; Humans ; Plasma ; Plasmapheresis ; Platelet Transfusion ; Plateletpheresis ; Red Cross* ; Tissue Donors